Ten reasons why you should use clarithromycin Review article
Article Sidebar
Published:
Jun 30, 2014
Keywords:
clarithromycin, the antibiotic
Main Article Content
Abstract
Clarithromycin is an antibiotic that prevents growth of the bacteria effectively, therefore we used for the treatment of infectious diseases. This substance has a very good pharmacokinetic properties. This preparation penetrating into the interior of macrophage white blood cells and interacts with the mechanisms responsible for the resistance body, which shows that in addition to its beneficial antibacterial activity are also valuable anti-inflammatory properties.
Article Details
How to Cite
Ratajczak, J. (2014). Ten reasons why you should use clarithromycin. Medycyna Faktow (J EBM), 7(2(23), 34-38. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2364
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ratajczak J.: Antybiotykoterapia w chorobach laryngologicznych. Alergoprofil 2008; 4(4): 9-19.
2. Dzierżanowska D., Jurkiewicz D., Zielnik-Jurkiewicz B.: Zakażenia w otolaryngologii. α-medica Press, Bielsko-Biała 2002; 240-250.
3. Anzueto A., Norris S.: Clarithromycin in 2003: sustained efficiency and safety in an era of rising antibiotic resistance. Int. J. Antimicrob. Agents 2004; 24(1): 1-17.
4. Alvarez-Elcoro S., Enzler M.J.: The Macrolides: Erythromycin, Clarithromycin, and Azithromycin. Mayo Clin. Proc. 1999; 74(6): 613-634.
5. Dzierżanowska D., Dzierżanowska-Fangrat K.: Przewodnik antybiotykoterapii 2011. α-medica Press, Bielsko-Biała 2011; 70-71.
6. Alahdab Y.O., Kalayci C.: Helicobacter pylori: Management in 2013. World J. Gastroenterol. 2014; 20(18): 5302-5307.
7. Górski N., Gromek I.: Zastosowanie makrolidów w leczeniu przewlekłego zapalenia zatok przynosowych. Mag. Otorynolaryng., wydanie specjalne – sierpień 2005: 3-15.
8. Bui K.Q., Banevicius M.A., Nightingale C.H. et al.: In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2000; 45(1): 57-62.
9. Tateda K., Hirakata Y., Furuya N. et al.: Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1993; 37(4): 675-680.
10. Post J.C. , Stoodley P., Hall-Stoodley L., Ehrlich G.D.: The role of biofilms in otolaryngologic infections. Curr. Opin. Otolaryngol. Head Neck Surg. 2004; 12(3): 185-190.
11. Hoover W.W., Barrett M.S., Jones R.N.: Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxy-clarithromycin. Diagn. Microbiol. Infect. Dis. 1992; 15(3): 259-266.
12. Rubin B.K.: The pharmacologic approach to airway clearance: mucoactive agents. Respir. Care 2002; 47(7): 818-822.
13. Jaffe A., Bush A.: Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol. 2001; 31(6): 464-473.
14. Postuła M.: Właściwości przeciwzapalne makrolidów. Mag. Otorynolaryng. 2007; 6(3): 67-74.
15. Shinkai M., Henke M.O., Rubin B.K.: Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol. Ther. 2008; 117(3): 393-405.
16. Garey K.W., Rubinstein I., Gotfried M.H. et al.: Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone- dependent asthma. Chest 2000; 118(6): 1826-1827.
17. Kraft M., Cassell G.H., Pak J., Martin R. J.: Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest. 2002; 121(6): 1782-1788.
18. Tamaoki J., Tagaya E., Sakai A., Konno K.: Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J. Allergy Clin. Immunol. 1995; 95(4): 853-859.
19. Takizawa H., Desaki M., Ohtoshi T. et al.: Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchialepithelial cells. Eur. Respir. J. 1998; 12(1): 57-63.
20. Terao H., Asano K., Kanai K. et al.: Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators Inflamm. 2003; 12(4): 195-202.
21. Kohri K., Tamaoki J., Kondo M. et al.: Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur. Respir. J. 2000; 15(1): 62-67.
22. Tamaoki J., Kondo M., Kohri K. et al.: Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J. Immunol. 1999; 163(5): 2909-2915.
2. Dzierżanowska D., Jurkiewicz D., Zielnik-Jurkiewicz B.: Zakażenia w otolaryngologii. α-medica Press, Bielsko-Biała 2002; 240-250.
3. Anzueto A., Norris S.: Clarithromycin in 2003: sustained efficiency and safety in an era of rising antibiotic resistance. Int. J. Antimicrob. Agents 2004; 24(1): 1-17.
4. Alvarez-Elcoro S., Enzler M.J.: The Macrolides: Erythromycin, Clarithromycin, and Azithromycin. Mayo Clin. Proc. 1999; 74(6): 613-634.
5. Dzierżanowska D., Dzierżanowska-Fangrat K.: Przewodnik antybiotykoterapii 2011. α-medica Press, Bielsko-Biała 2011; 70-71.
6. Alahdab Y.O., Kalayci C.: Helicobacter pylori: Management in 2013. World J. Gastroenterol. 2014; 20(18): 5302-5307.
7. Górski N., Gromek I.: Zastosowanie makrolidów w leczeniu przewlekłego zapalenia zatok przynosowych. Mag. Otorynolaryng., wydanie specjalne – sierpień 2005: 3-15.
8. Bui K.Q., Banevicius M.A., Nightingale C.H. et al.: In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2000; 45(1): 57-62.
9. Tateda K., Hirakata Y., Furuya N. et al.: Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1993; 37(4): 675-680.
10. Post J.C. , Stoodley P., Hall-Stoodley L., Ehrlich G.D.: The role of biofilms in otolaryngologic infections. Curr. Opin. Otolaryngol. Head Neck Surg. 2004; 12(3): 185-190.
11. Hoover W.W., Barrett M.S., Jones R.N.: Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxy-clarithromycin. Diagn. Microbiol. Infect. Dis. 1992; 15(3): 259-266.
12. Rubin B.K.: The pharmacologic approach to airway clearance: mucoactive agents. Respir. Care 2002; 47(7): 818-822.
13. Jaffe A., Bush A.: Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol. 2001; 31(6): 464-473.
14. Postuła M.: Właściwości przeciwzapalne makrolidów. Mag. Otorynolaryng. 2007; 6(3): 67-74.
15. Shinkai M., Henke M.O., Rubin B.K.: Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol. Ther. 2008; 117(3): 393-405.
16. Garey K.W., Rubinstein I., Gotfried M.H. et al.: Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone- dependent asthma. Chest 2000; 118(6): 1826-1827.
17. Kraft M., Cassell G.H., Pak J., Martin R. J.: Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest. 2002; 121(6): 1782-1788.
18. Tamaoki J., Tagaya E., Sakai A., Konno K.: Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J. Allergy Clin. Immunol. 1995; 95(4): 853-859.
19. Takizawa H., Desaki M., Ohtoshi T. et al.: Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchialepithelial cells. Eur. Respir. J. 1998; 12(1): 57-63.
20. Terao H., Asano K., Kanai K. et al.: Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators Inflamm. 2003; 12(4): 195-202.
21. Kohri K., Tamaoki J., Kondo M. et al.: Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur. Respir. J. 2000; 15(1): 62-67.
22. Tamaoki J., Kondo M., Kohri K. et al.: Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J. Immunol. 1999; 163(5): 2909-2915.